list of glp 1 agonists Market Overview: GLP-1 and the Obesity Market | Blog Glucagon-like peptide-1 receptor agonists(GLP-1RAs)** GLP-1

Polonsky, PhD, CDCES & Susan Guzman, PhD (Behavioral Diabetes Institute) that reveals psychosocial forces behind diabetes self-management tools to break through resistance and inspire change

Market Outlook and Strategic Insights The obesity and weight loss treatment landscape will undergo substantial transformation in the coming years

Approved by the U.S

Cardiovascular outcomes (e.g., SELECT and SOUL trials), 2

Medical Safety and Oversight Every GLP-1 therapy requires a professional medical evaluation

This shift could drive the obesity market to exceed $100 billion annually, reducing overall healthcare costs by addressing comorbidities associated with obesity